Coldstream Laboratories for Parental Dosage Forms NCI Contract - - BioPharm International

ADVERTISEMENT

Coldstream Laboratories for Parental Dosage Forms NCI Contract



Coldstream Laboratories, a provider of sterile drug-product development and manufacturing services, has been awarded a five-year contract with the National Cancer Institute (NCI), with the objective of developing and producing pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products.

Coldstream Laboratories, based in Lexington, Kentucky, is a privately held CMO. It was formed in 2007 as a spin off from the University of Kentucky's Center for Pharmaceutical Sciences and Technology.

Source: Coldstream Laboratories

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines

Click here